(WCH) Wacker Chemie - Overview
Stock: Silanes, Siloxanes, Silicone Fluids, Polymer Powders, Polysilicon
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.81% |
| Yield on Cost 5y | 2.36% |
| Yield CAGR 5y | 5.74% |
| Payout Consistency | 80.4% |
| Payout Ratio | 5.8% |
| Risk 5d forecast | |
|---|---|
| Volatility | 37.2% |
| Relative Tail Risk | -5.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.34 |
| Alpha | 2.56 |
| Character TTM | |
|---|---|
| Beta | 0.321 |
| Beta Downside | 0.543 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.48% |
| CAGR/Max DD | -0.31 |
Description: WCH Wacker Chemie January 12, 2026
Wacker Chemie AG (XETRA: WCH) is a Munich-based specialty chemicals group operating through four business units: Silicones, Polymers, Biosolutions, and Polysilicon. The Silicones segment supplies a full range of silanes, siloxanes, fluids, emulsions, elastomers, resins and pyrogenic silica; Polymers delivers binders and polymeric additives for construction, paper, coatings and adhesives; Biosolutions produces custom biotech and fine-chemical products such as pharmaceutical proteins, vaccines, cyclodextrins and specialty resins; while Polysilicon manufactures hyper-pure silicon for semiconductor and solar-cell applications.
Key recent metrics: 2023 revenue reached €6.6 bn, with an adjusted EBITDA margin of roughly 12 %, driven largely by strong demand for silicone intermediates in automotive electronics and a rebound in solar-grade polysilicon volumes as global PV installations accelerated. The silicone market is projected to grow at a 5-6 % CAGR through 2028, supported by expanding use in medical devices and high-performance coatings. Conversely, polysilicon profitability remains sensitive to silicon-price cycles and the pace of renewable-energy policy incentives in Europe and the U.S.
Wacker’s diversified product mix and its ownership by the Dr. Alexander Wacker Familiengesellschaft provide a stable governance structure, but the company’s exposure to cyclical raw-material costs (e.g., methyl chloride for silanes) adds a layer of earnings volatility.
For a deeper quantitative assessment, the ValueRay platform offers up-to-date valuation models and scenario analysis that can help you gauge WCH’s risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 21.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.08 > 0.02 and ΔFCF/TA -1.36 > 1.0 |
| NWC/Revenue: 42.63% < 20% (prev 40.43%; Δ 2.20% < -1%) |
| CFO/TA 0.05 > 3% & CFO 386.4m > Net Income 21.7m |
| Net Debt (-719.9m) to EBITDA (561.7m): -1.28 < 3 |
| Current Ratio: 3.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.7m) vs 12m ago -0.29% < -2% |
| Gross Margin: 15.28% > 18% (prev 0.15%; Δ 1512 % > 0.5%) |
| Asset Turnover: 63.61% > 50% (prev 64.53%; Δ -0.91% > 0%) |
| Interest Coverage Ratio: 0.70 > 6 (EBITDA TTM 561.7m / Interest Expense TTM 124.9m) |
Altman Z'' 4.42
| A: 0.28 (Total Current Assets 3.55b - Total Current Liabilities 1.17b) / Total Assets 8.56b |
| B: 0.46 (Retained Earnings 3.90b / Total Assets 8.56b) |
| C: 0.01 (EBIT TTM 87.4m / Avg Total Assets 8.75b) |
| D: 1.00 (Book Value of Equity 4.16b / Total Liabilities 4.14b) |
| Altman-Z'' Score: 4.42 = AA |
Beneish M -2.91
| DSRI: 1.26 (Receivables 1.04b/854.8m, Revenue 5.57b/5.77b) |
| GMI: 1.00 (GM 15.28% / 15.22%) |
| AQI: 0.96 (AQ_t 0.18 / AQ_t-1 0.19) |
| SGI: 0.96 (Revenue 5.57b / 5.77b) |
| TATA: -0.04 (NI 21.7m - CFO 386.4m) / TA 8.56b) |
| Beneish M-Score: -2.91 (Cap -4..+1) = A |
What is the price of WCH shares?
Over the past week, the price has changed by -6.37%, over one month by -3.29%, over three months by -0.72% and over the past year by +10.57%.
Is WCH a buy, sell or hold?
What are the forecasts/targets for the WCH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 69.9 | 1.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 64.8 | -6.2% |
WCH Fundamental Data Overview February 03, 2026
P/E Trailing = 167.7273
P/E Forward = 21.9298
P/S = 0.6863
P/B = 0.8487
P/EG = 2.86
Revenue TTM = 5.57b EUR
EBIT TTM = 87.4m EUR
EBITDA TTM = 561.7m EUR
Long Term Debt = 1.77b EUR (from longTermDebt, last quarter)
Short Term Debt = 162.6m EUR (from shortTermDebt, last quarter)
Debt = 1.94b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -719.9m EUR (from netDebt column, last quarter)
Enterprise Value = 5.04b EUR (3.82b + Debt 1.94b - CCE 719.9m)
Interest Coverage Ratio = 0.70 (Ebit TTM 87.4m / Interest Expense TTM 124.9m)
EV/FCF = -7.38x (Enterprise Value 5.04b / FCF TTM -682.7m)
FCF Yield = -13.55% (FCF TTM -682.7m / Enterprise Value 5.04b)
FCF Margin = -12.26% (FCF TTM -682.7m / Revenue TTM 5.57b)
Net Margin = 0.39% (Net Income TTM 21.7m / Revenue TTM 5.57b)
Gross Margin = 15.28% ((Revenue TTM 5.57b - Cost of Revenue TTM 4.72b) / Revenue TTM)
Gross Margin QoQ = 11.50% (prev 11.70%)
Tobins Q-Ratio = 0.59 (Enterprise Value 5.04b / Total Assets 8.56b)
Interest Expense / Debt = 0.93% (Interest Expense 18.0m / Debt 1.94b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 65.5m (EBIT 87.4m * (1 - 25.00%))
Current Ratio = 3.02 (Total Current Assets 3.55b / Total Current Liabilities 1.17b)
Debt / Equity = 0.45 (Debt 1.94b / totalStockholderEquity, last quarter 4.27b)
Debt / EBITDA = -1.28 (Net Debt -719.9m / EBITDA 561.7m)
Debt / FCF = 1.05 (negative FCF - burning cash) (Net Debt -719.9m / FCF TTM -682.7m)
Total Stockholder Equity = 4.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.25% (Net Income 21.7m / Total Assets 8.56b)
RoE = 0.49% (Net Income TTM 21.7m / Total Stockholder Equity 4.47b)
RoCE = 1.40% (EBIT 87.4m / Capital Employed (Equity 4.47b + L.T.Debt 1.77b))
RoIC = 1.35% (NOPAT 65.5m / Invested Capital 4.87b)
WACC = 4.95% (E(3.82b)/V(5.76b) * Re(7.10%) + D(1.94b)/V(5.76b) * Rd(0.93%) * (1-Tc(0.25)))
Discount Rate = 7.10% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
Fair Price DCF = unknown (Cash Flow -682.7m)
EPS Correlation: -89.24 | EPS CAGR: -61.96% | SUE: -3.65 | # QB: 0
Revenue Correlation: -68.52 | Revenue CAGR: -5.97% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.28 | Chg30d=-0.530 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=2.14 | Chg30d=+0.470 | Revisions Net=-1 | Growth EPS=+413.2% | Growth Revenue=+1.2%